` PALI (Palisade Bio Inc) vs S&P 500 Comparison - Alpha Spread

PALI
vs
S&P 500

Over the past 12 months, PALI has underperformed S&P 500, delivering a return of -83% compared to the S&P 500's +13% growth.

Stocks Performance
PALI vs S&P 500

Loading
PALI
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
PALI vs S&P 500

Loading
PALI
S&P 500
Difference
www.alphaspread.com

Performance By Year
PALI vs S&P 500

Loading
PALI
S&P 500
Add Stock

Competitors Performance
Palisade Bio Inc vs Peers

S&P 500
PALI
LLY
JNJ
NOVO B
ROG
Add Stock

Palisade Bio Inc
Glance View

Market Cap
3.6m USD
Industry
Pharmaceuticals

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 13 full-time employees. The company went IPO on 2006-12-20. The firm is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.

PALI Intrinsic Value
2.5185 USD
Undervaluation 70%
Intrinsic Value
Price
Back to Top